3D bioprinting just got easier – and research could benefit

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

New entry-level 3D printer aims to make bioprinting more accessible to researchers and manufacturers for uses that range from personalised drugs to human spare parts.

Finland-based bioprinting startup Brinter has today announced the launch of its new entry-level model, Brinter Core. The multi-material 3D bioprinting solution is designed to be more portable and, at half the cost of its predecessor, could allow more pharmaceutical companies, hospitals, universities and research centres to access the technology under tight budget restrictions.

Longevity.Technology: Brinter Core is a modular and portable bioprinter that is able to print multi-material and highly complex tissue structures in 3D, providing all the basic features needed for bioprinting. The device can print both stiff and soft materials, including, but not limited to, liquids and hydrogels with living cells, bio-paste, metal with binder material and plastic.

The market is growing strongly as accelerated technological, material and methodological developments expand the potential applications for 3D-bioprinting. However, many institutions are unable to acquire 3D printing technology due to its price point, so it’s good to see reasonably-priced tech like Brinter Core hit the market – reasonably priced, transportable, capable and less space-consuming than alternatives. Brinter also claim it can speed up scientific development by a factor of up to ten.

“We really want to open up the 3D bioprinting market in a way that’s never been done before,” says Brinter CEO Tomi Kalpio. “Researchers and companies need to deliver products for 3D bioprinting, but many don’t have 3D printers with unlimited bioinks and other materials yet due to their significant cost and difficulty moving them between labs. With the Brinter Core, we make 3D bioprinting a reality and get started for those that previously were boxed out of the market,” he continues.

Brinter printer
Brinter Core inks and parts

The benefits of 3D bioprinting range from cancer research to printing human “spare parts” such as kidneys, hearts, or even brains. The company aims to help save more lives through more personalised treatment. For example, researchers can print 3D cancerous cells and track how they communicate with each other, allowing researchers to identify the best individual drugs to treat the disease.

With a nod to sustainability, Brinter Core performs many of the same functions as its predecessor, using the same printing heads, meaning upgrades are available if required, and heads can be easily swapped between Brinter products without any tools. Available printing technologies include, for example, valve-free pneumatic extrusion (Pneuma Tool), screw-driven mechanical extrusion (Visco Tool), solenoid-driven dispensing (MicroDroplet Tool) and thermoplastic granulate extrusion (Granu Tool).

“Medical research facilities and universities often still rely on traditional methods of discovery in the research of new drugs, understanding diseases, and finding medical ways to help people. Drug developers are excited to get their hands on the device to do fast prototyping and testing and deliver treatments that save more lives,” says Pirkko Härkönen, Counsellor, Institute of Biomedicine, MD, PhD, Professor emeritus.

Customers of the company include bio and pharmaceutical companies such as Nanoform, as well as a long list of research organisations  that includes VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, University of Turku, Åbo Akademi, Tampere University and the University of Helsinki.

To date, Brinter has raised a total of €1.2m in funding and is currently active in over 10 countries, including the USA, Germany, India and the UK.

Images courtesy of Brinter
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Printers that can now print DNA

DNA Script obtains CE Mark for SYNTAX DNA printing platform. DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the...

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Young blood: discover the possibilities of plasma based therapy

The evolution of plasma-based therapeutics is accelerating – our FREE report cuts through the young blood hype for the lowdown on the latest therapies. Our...

Longevica raises $2.5 million for open research platform

$2.5m in funding to support longevity research platform and study to accelerate the discovery of life extension mechanisms, launching in 2022. Longevica, a life science...

    Subscribe to our newsletter